Med BioGene’s lead product under development is LungExpress Dx™, a test for early-stage non-small-cell lung cancer that analyzes the molecular profile of a patient’s tumour to provide information to assist in tailoring treatment for that specific patient.  LungExpress Dx™ is the first and only gene expression-based test for non-small-cell lung cancer shown to assist in determining a patient's benefit from chemotherapy and prognosis for survival.

Med BioGene expects to commercialize LungExpress Dx™ in the United States in the second half of 2009.